Oct 28, 2017
PARADIGMS data also show patients treated with Gilenya had significantly fewer new brain lesions vs. those on interferon beta-1a
PARADIGMS data also show patients treated with Gilenya had significantly fewer new brain lesions vs. those on interferon beta-1a
Currently there are no specifically approved disease modifying therapies for children and adolescents with MS, a population at high risk of long-term disability
MS is a highly debilitating disease which touches every aspect of young patients’ daily lives, from school performance to family relations and friendships.
READ MORE —
:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
MS Views and News provides Multiple Sclerosis education, information, resources and services that will benefit many affected by MS.
:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews